1. Home
  2. AVTX vs ARMP Comparison

AVTX vs ARMP Comparison

Compare AVTX & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVTX
  • ARMP
  • Stock Information
  • Founded
  • AVTX 2011
  • ARMP N/A
  • Country
  • AVTX United States
  • ARMP United States
  • Employees
  • AVTX N/A
  • ARMP N/A
  • Industry
  • AVTX Biotechnology: Pharmaceutical Preparations
  • ARMP Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • AVTX Health Care
  • ARMP Health Care
  • Exchange
  • AVTX Nasdaq
  • ARMP Nasdaq
  • Market Cap
  • AVTX 88.4M
  • ARMP 80.0M
  • IPO Year
  • AVTX 2015
  • ARMP N/A
  • Fundamental
  • Price
  • AVTX $7.35
  • ARMP $1.95
  • Analyst Decision
  • AVTX Strong Buy
  • ARMP Strong Buy
  • Analyst Count
  • AVTX 4
  • ARMP 1
  • Target Price
  • AVTX $33.00
  • ARMP $7.00
  • AVG Volume (30 Days)
  • AVTX 55.8K
  • ARMP 7.9K
  • Earning Date
  • AVTX 03-28-2025
  • ARMP 03-20-2025
  • Dividend Yield
  • AVTX N/A
  • ARMP N/A
  • EPS Growth
  • AVTX N/A
  • ARMP N/A
  • EPS
  • AVTX N/A
  • ARMP N/A
  • Revenue
  • AVTX $820,000.00
  • ARMP $5,467,000.00
  • Revenue This Year
  • AVTX N/A
  • ARMP $23.87
  • Revenue Next Year
  • AVTX N/A
  • ARMP N/A
  • P/E Ratio
  • AVTX N/A
  • ARMP N/A
  • Revenue Growth
  • AVTX N/A
  • ARMP 34.92
  • 52 Week Low
  • AVTX $4.18
  • ARMP $1.80
  • 52 Week High
  • AVTX $34.46
  • ARMP $4.48
  • Technical
  • Relative Strength Index (RSI)
  • AVTX 42.79
  • ARMP 42.06
  • Support Level
  • AVTX $7.42
  • ARMP $1.89
  • Resistance Level
  • AVTX $8.50
  • ARMP $2.08
  • Average True Range (ATR)
  • AVTX 0.64
  • ARMP 0.10
  • MACD
  • AVTX 0.02
  • ARMP -0.01
  • Stochastic Oscillator
  • AVTX 17.16
  • ARMP 18.18

About AVTX Avalo Therapeutics Inc.

Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

About ARMP Armata Pharmaceuticals Inc.

Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.

Share on Social Networks: